N-cyclopropyl-4-tert-butylbenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-cyclopropyl-4-tert-butylbenzamide
• 英文别名: 4-tert-butyl-N-cyclopropylbenzamide
• 化学式: C₁₄H₁₉NO
• mdl: MFCD02919805
• 分子量: 217.311
• InChiKey: XTUAPAIXLWGBPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-cyclopropyl-4-tert-butylbenzamide 在 水 、 tert-butylammonium hexafluorophosphate(V) 作用下， 以 乙腈 为溶剂， 以76 %的产率得到4-(tert-butyl)-N-formylbenzamide
  参考文献：
  名称：

  单原子铁催化剂作为有机电合成阳极氧化的高级氧化还原介体

  摘要：

  我们合成了一种单原子铁催化剂（Fe-SA@NC），作为先进的氧化还原介体，它在有机电氧化中表现出良好的转化效率。这项研究为从无机化学方面设计有机串联反应的催化系统提供了宝贵的见解。

  DOI：

  10.1002/anie.202404295
• 作为产物：
  描述：

  环丙胺 、 对叔丁基苯甲酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-cyclopropyl-4-tert-butylbenzamide
  参考文献：
  名称：

  Cooperative Photoredox and Cobalt‐catalyzed Acceptorless Dehydrogenative Functionalization of Cyclopropylamides towards Allylic N,O‐Acyl‐acetal Derivatives

  摘要：

  We disclose herein a novel photoredox and cobalt co‐catalyzed ring‐opening/acceptorless dehydrogenative functionalization of mono‐donor cyclopropanes, which providing a sustainable and atom‐economic approach to rapidly assemble a wide range of allylic N,O‐acyl‐acetal derivatives. The optimized conditions accommodate assorted cycloalkylamides and primary, secondary and tertiary alcohols, with applications in late‐stage functionalization of pharmaceutically relevant compounds, stimulating the further utility in medicinal chemistry. Moreover, selective nucleophilic substitutions with various carbon nucleophiles were succeed in a one‐pot fashion, offering a reliable avenue to access some cyclic and acyclic derivatives.

  DOI：

  10.1002/anie.202401579

文献信息

• Heterobicyclic pyrazole compounds and methods of use
  申请人：Blake F. James

  公开号：US20070238726A1

  公开（公告）日：2007-10-11

  Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  化合物Ia和Ib的结构，以及其立体异构体、几何异构体、互变异构体、溶剂合物、代谢物和药学上可接受的盐，可用于抑制受体酪氨酸激酶并治疗由此介导的疾病。公开了使用化合物Ia和Ib的结构，以及其立体异构体、几何异构体、互变异构体、溶剂合物和药学上可接受的盐的方法，用于体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病，或相关的病理条件。
• NOVEL COMPOUNDS AS GPR119 AGONISTS
  申请人：Mankind Pharma Ltd.

  公开号：US20170291910A1

  公开（公告）日：2017-10-12

  The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.

  本发明涉及式(I)的新化合物作为GPR119激动剂，包含此类化合物的组合物及其制备方法。
• N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS
  申请人：Li Yun-Long

  公开号：US20120157430A1

  公开（公告）日：2012-06-21

  The present invention provides N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

  本发明提供了调节磷脂酰肌醇3-激酶（PI3Ks）活性并且在治疗与PI3Ks活性相关的疾病方面有用的N-(1-(取代苯基)乙基)-9H-嘌呤-6-胺衍生物，例如炎症性疾病、免疫性疾病、癌症和其他疾病。
• [EN] NOVEL APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASE 1 DE RÉGULATION DE SIGNAL D'APOPTOSE
  申请人：MANKIND PHARMA LTD

  公开号：WO2020261294A1

  公开（公告）日：2020-12-30

  The present invention relates to inhibitors of apoptosis signal-regulating kinase 1 ("ASK1"), a process for synthesis of the compounds of the present invention, composition comprising the compounds and use of the compounds for inhibition of ASK1.

  本发明涉及凋亡信号调节激酶1（"ASK1"）的抑制剂，一种合成本发明化合物的方法，包含该化合物的组合物以及利用该化合物抑制ASK1的用途。
• CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1
  申请人：Aicher Thomas Daniel

  公开号：US20090111800A1

  公开（公告）日：2009-04-30

  The present invention discloses novel compounds of Formula (I): having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11β-HSD type 1 activity.

  本发明公开了具有11β-HSD类型1拮抗活性的Formula (I)的新化合物，以及制备这种化合物的方法。在另一实施例中，该发明公开了包含Formula (I)化合物的药物组合物，以及利用这些化合物和组合物治疗糖尿病、高血糖、肥胖、高血压、高脂血症、代谢综合征以及与11β-HSD类型1活性相关的其他疾病的方法。